Company intelligence / Profile preview

ProteoSys

Ownership: Private
Employees: ~2
Development stage: Commercial

Overview

ProteoSys is a German biotechnology research company specializing in cell biology and proteomics. It has developed novel biomarkers such as Annexin 3 for non-invasive diagnosis of prostate cancer, aiming to reduce unnecessary biopsies by providing more specific confirmatory tests. The company has also worked on projects related to breast cancer, neurodegenerative diseases, and embryo toxicity testing systems. A key partnership with bioMérieux was established to develop a urine-based diagnostic test using their proprietary ANXA 3 biomarker technology.

Therapeutic areas: OncologyNeurologyWomen's Health
Modalities: Diagnostic testBiomarker-based diagnostics
Industry: Protein Biomarker Diagnostics

Partnerships

bioMérieux – license/development agreement for ANXA 3 prostate cancer diagnostic test development on VIDAS® platform.

Beyond the preview

Go deeper on ProteoSys.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ProteoSys.

Explore the full profile